CN110151815A - 含光皮树提取物的制剂及其应用 - Google Patents
含光皮树提取物的制剂及其应用 Download PDFInfo
- Publication number
- CN110151815A CN110151815A CN201910378567.5A CN201910378567A CN110151815A CN 110151815 A CN110151815 A CN 110151815A CN 201910378567 A CN201910378567 A CN 201910378567A CN 110151815 A CN110151815 A CN 110151815A
- Authority
- CN
- China
- Prior art keywords
- preparation
- wilson dogwood
- renal tubular
- hepatic fibrosis
- wilson
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 239000000284 extract Substances 0.000 title claims abstract description 14
- 240000006766 Cornus mas Species 0.000 title 1
- 241000209020 Cornus Species 0.000 claims abstract description 54
- 206010019668 Hepatic fibrosis Diseases 0.000 claims abstract description 23
- 208000031816 Pathologic Dilatation Diseases 0.000 claims abstract description 23
- 208000011580 syndromic disease Diseases 0.000 claims abstract description 23
- 210000004185 liver Anatomy 0.000 claims description 29
- VZGDMQKNWNREIO-UHFFFAOYSA-N carbon tetrachloride Substances ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 11
- 150000002632 lipids Chemical class 0.000 claims description 9
- 238000002347 injection Methods 0.000 claims description 7
- 239000007924 injection Substances 0.000 claims description 7
- 235000013305 food Nutrition 0.000 claims description 6
- 230000036541 health Effects 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000000835 fiber Substances 0.000 claims description 4
- 238000013459 approach Methods 0.000 claims description 3
- 235000013399 edible fruits Nutrition 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 239000000443 aerosol Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 239000007928 intraperitoneal injection Substances 0.000 claims description 2
- 238000010253 intravenous injection Methods 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 abstract description 2
- 239000003921 oil Substances 0.000 description 33
- 235000019198 oils Nutrition 0.000 description 33
- 241000699666 Mus <mouse, genus> Species 0.000 description 18
- 238000012360 testing method Methods 0.000 description 17
- 210000002966 serum Anatomy 0.000 description 12
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 10
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 7
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 7
- 238000004043 dyeing Methods 0.000 description 7
- 230000003908 liver function Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 7
- 102000008186 Collagen Human genes 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 229920001436 collagen Polymers 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000019197 Superoxide Dismutase Human genes 0.000 description 5
- 108010012715 Superoxide dismutase Proteins 0.000 description 5
- 208000019425 cirrhosis of liver Diseases 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 229960003180 glutathione Drugs 0.000 description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 210000005229 liver cell Anatomy 0.000 description 4
- 239000004006 olive oil Substances 0.000 description 4
- 235000008390 olive oil Nutrition 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 3
- 108010028554 LDL Cholesterol Proteins 0.000 description 3
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 3
- 239000005642 Oleic acid Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 3
- 235000020778 linoleic acid Nutrition 0.000 description 3
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 2
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 2
- 208000002353 alcoholic hepatitis Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000002300 anti-fibrosis Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 206010057573 Chronic hepatic failure Diseases 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 102000002734 Collagen Type VI Human genes 0.000 description 1
- 108010043741 Collagen Type VI Proteins 0.000 description 1
- 208000010334 End Stage Liver Disease Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 206010019837 Hepatocellular injury Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 208000011444 chronic liver failure Diseases 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 210000000720 eyelash Anatomy 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 210000004024 hepatic stellate cell Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000004900 laundering Methods 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 231100000849 liver cell damage Toxicity 0.000 description 1
- 208000018191 liver inflammation Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
- 208000007232 portal hypertension Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229940099456 transforming growth factor beta 1 Drugs 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/40—Cornaceae (Dogwood family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Botany (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Pediatric Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明属于制剂领域，提供了一种含光皮树提取物的制剂及其应用，所述光皮树提取物如光皮树油。本发明提供的含有光皮树提取物的制剂能够有效改善肝脏纤维化的情况，为肝脏纤维化的治疗带来新途径。
Description
技术领域
本发明属于制剂领域，涉及光皮树提取物的应用。
背景技术
我国是肝脏慢性疾病大国。肝脏纤维化是很多肝脏慢性疾病的病理发展过程的一环，例如病毒性肝炎、毒素导致的肝损伤、酒精性肝炎、非酒精性肝炎等。随着肝脏纤维化的进展，可能导致肝硬化、门静脉高压、肝脏功能失代偿、肝脏肿瘤，甚至死亡。每年有超过一百万人因此病死亡，特别是对终末期肝病，尚无有效的逆转药物。肝移植成了最有效的方法，然而供体不足使很多病人在等待的过程中死亡。因此，针对此类疾病的药物研发迫在眉睫。
发明内容
本申请发明人对光皮树提取物的抗纤维化作用进行了研究，经实验验证，提供一种改善肝脏纤维化的新方式。
在第一个方面，本发明提供一种抗肝脏纤维化的制剂，所述制剂包括光皮树提取物。
在第二个方面，本发明提供光皮树提取物在制备抗肝脏纤维化制剂中的应用。
优选地，所述光皮树提取物是光皮树油；更优选地，所述光皮树油是从光皮树的果实和种子中萃取出的脂质物质。
优选地，所述肝脏纤维化是由CCl4(四氯化碳)诱导的。
优选地，所述制剂是食品、药物或保健品。
优选地，所述制剂是药物时，所述制剂为口服、注射或灌胃途径给药；进一步优选地，所述注射为静脉注射或腹腔注射。
优选地，所述药物的剂型为片剂、胶囊剂、粉针、注射剂或气雾剂。
优选地，所述药物还包括一种或多种制药学上可接受的辅料，如稀释剂、粘合剂、润湿剂、崩解剂、溶剂和/或缓冲剂等。本领域技术人员可以根据实际需要选择合适的辅料和量，以制备适用的药物。
优选地，当所述制剂是食品或保健品时，还包括一种或多种制剂学上可接受的辅料，如填充剂、口味改善剂、溶剂和/或缓冲剂等。本领域技术人员可以根据实际需要选择合适的辅料和量，以制备适用的食品或保健品。
优选地，所述抗肝脏纤维化指预防、治疗肝脏纤维化或改善肝脏纤维化状态。
本发明的提供的含有光皮树油的制剂能够有效改善肝脏纤维化的情况，为肝脏纤维化的治疗带来新途径。
附图说明
图1：实施例二中肝功能指标、血脂指标检测结果，其中A为ALT检测结果，B为AST检测结果，以上二者为肝功能指标。C为TG检测结果，D为TC检测结果，E为HDL-C检测结果，F为LDL-C检测结果，以上四者为血脂指标。其中，*代表P＜0.05；**代表P＜0.01。
图2：实施例二中的血清肝纤指标检测结果，其中，A为PCIII检测结果，B为IV-C检测结果，C为LN检测结果。
图3：实施例二中的抗氧化能力指标检测结果，其中，A为SOD检测结果，B为MDA检测结果，C为GSH检测结果。
图4：对肝脏组织分别进行HE染色、天狼星红染色和Masson染色的结果。
图5：实施例二中的蛋白质印记实验结果，其中A为α-SMA检测结果，B为TGF-β1检测结果。
具体实施方式
以下将结合具体实施例来说明本发明的内容，但本发明的范围不限于此。任何基于本发明思路的技术方案均落入本发明的范围内。
如果没有特殊说明，以下实施例中使用的任何试剂和仪器均是本领域常规试剂和仪器，可以通过商购途径获得。任何方法均是本领域常规方法，本领域技术人员根据实施例内容可以毫无疑义地实施本方法并获得对应的结果。
光皮树油是从光皮树(光皮梾木)果实和种子中萃取出的脂质物质，主要含油酸和亚油酸等活性成分，可治疗高脂血症(高血压、冠心病)，对降低胆固醇有显著效果，其中不饱和脂肪酸具有抗氧化和改善脂质过氧化损伤的作用。但现在光皮树油抗肝脏纤维化作用研究尚未见报道。为了观察光皮树油的抗纤维化作用，以下实施例将采用CCl4诱发的肝纤维化动物模型，研究光皮树油对肝纤维化的治疗作用。
以下实施例中使用的小鼠为C57BL/6J小鼠，由湖南斯莱克景达实验动物有限公司提供，许可证号：SCXK(湘)2016-0002。小鼠饲养于SPF级实验室。
使用的光皮树油来自湖南省林业科学院；光皮树油脂肪酸组成以油酸(35.71％)和亚油酸(44.49％)为主，油酸和亚油酸都属于不饱和脂肪酸；另含有益因子：植物甾醇(1.98mg/g)、鲨烯(0.0324mg/g)、维生素E(60.556mg/g)。
CCl4(编号：C112040)、橄榄油(编号：O108686)购自阿拉丁公司，HE染色试剂盒(编号：G1120)、天狼星红染色试剂盒(编号：G1471)、Masson三色染色试剂盒(编号：G1340)均购自Solarbio公司。β-肌动蛋白(编号：60008.I.AP)购自Proteintech公司，α-SMA(编号：ab32575)和TGFβ1(编号：ab215715)购自abcam公司。
实施例一：实验动物分组及处理
选取小鼠，清洁级饲养,1周适应期后随机分为4组，分别为：
正常组(NC)：橄榄油对照组，7只；
模型组(Model)：CCl4组，5只；
低剂量光皮树油组(LDG)：CCl4+低剂量光皮树油(2mg/kg)组，6只；
高剂量光皮树油组(HDG)：CCl4+高剂量光皮树油(10mg/kg)组，6只。
以上后三组的CCl4给药为：CCl4以20％溶解于橄榄油，每周2次腹腔注射，剂量为5mL/kg。正常组注射等量橄榄油。光皮树油用法为按相应剂量每天灌胃处理。持续给药6周后处死小鼠，收集血清及肝脏标本。
实施例二：测试项目
对实施例一收集到的血清和肝脏标本进行检测，检测项目和检测方法如下：
肝功能指标、血脂指标由中南大学湘雅二医院检验科检测；
血清肝纤指标由中南大学湘雅二医院传染科实验室检测；
抗氧化指标采用南京建成生物工程研究所试剂盒按说明书方法检测；
小鼠肝脏切片的染色均是根据相应染色试剂盒说明书方法进行染色；
使用蛋白质印迹法检测蛋白表达水平。
检测结果见表1，具体说明如下所示：
2.1肝功能指标
图1的A和B显示了肝功能指标谷丙转氨酶(ALT)、谷草转氨酶(AST)的检测结果。由图可知，模型组ALT、AST的含量与对正常组比较差异有统计学意义(P＜0.05)，说明造模成功；光皮树油的低、高剂量组血清ALT、AST含量均低于模型组，与模型组比较，差异有统计学意义(P＜0.05)。说明光皮树油可以保护肝功能。
2.2血脂指标
血脂指标的检测结果由图1的C～F给出，其中，与正常组比较，模型组和光皮树油的低、高剂量组在甘油三酯(TG)、总胆固醇(TC)、高密度脂蛋白(HDL-C)的含量这三项无明显差别(P＞0.05)，见图1C、1D、1E；关于低密度脂蛋白(LDL-C)这项，模型组的含量高于正常组含量，同时高剂量光皮树油组的LDL-C含量与模型组相比有统计学意义(P＜0.05)，见图1F。说明高剂量光皮树油可以降低血清低密度脂蛋白，有利于改善血脂情况。
2.3血清肝纤指标
血清肝纤指标包括III型前胶原(PCIII)、层黏蛋白(LN)和IV型胶原(IV-C)。如图2的A、B和C所示，模型组与正常组比较，小鼠血清PCIII、IV-C和LN含量明显升高增加(P<0.05)；低剂量光皮树油组可在一定程度上降低小鼠血清PCIII和IV-C含量(P<0.01)；高剂量光皮树油组能明显降低血清PCIII、IV-C和LN含量(P<0.01)。说明光皮树油可以降低肝纤相关的血清指标，表明光皮树油可以减轻CCl4诱导的小鼠肝脏纤维化情况。
2.4抗氧化能力指标
抗氧化能力指标包括超氧化物歧化酶(SOD)、丙二醛(MDA)、谷胱甘肽(GSH)。由图3B可知，模型组的肝脏MDA含量高于正常组，同时光皮树油高、低剂量组的MDA低于模型组(P＜0.05)。由图3A和C可知，模型组的肝脏SOD、GSH含量低于正常组，同时光皮树油高、低剂量组的SOD、GSH高于模型组(P＜0.05)。说明CCl4诱导小鼠肝脏纤维化可以减轻小鼠肝脏的抗氧化能力，而光皮树油可以增强肝脏纤维化小鼠肝脏的抗氧化能力。
2.5小鼠肝脏HE染色
将小鼠肝脏组织按照常规步骤进行HE染色，结果如图4第1行所示，其中，正常组：肝细胞以中央静脉为中心呈放射状排列，肝小叶结构正常，未见肝细胞变性及炎症细胞浸润；模型组：肝索排列紊乱，可见明显纤维间隔形成，胶原明显增生，肝细胞明显肿胀变性，其中多为脂肪变性，多分布于界板周围，间质内见炎症细胞浸润；高剂量光皮树油组：肝小叶结构存在，有少量纤维间隔，少量肝细胞脂肪变性，轻度炎细胞浸润；低剂量光皮树油可见纤维间隔形成，胶原增生较明显，肝细胞肿胀，间质内见中度炎症浸润。
由图可见，光皮树油可以改善小鼠肝细胞受损情况，同时减轻肝脏炎症。
2.6小鼠肝脏天狼星红染色、Masson染色
将小鼠肝脏组织进行天狼星红染色(Sirius red)和Masson染色镜检，结果如图4的第2行和第3行所示。正常组仅汇管区见少量胶原；模型组胶原明显增生，形成完整的纤维间隔，正常小叶结构被破坏。高剂量光皮树油组可见少量胶原增生，少量纤维间隔形成，说明光皮树油可以减轻肝纤维化的形成；低剂量光皮树油可见胶原增生较明显，不完整的纤维间隔形成，肝小叶结构稍破坏。
2.7小鼠肝脏α-SMA(α-平滑肌激动蛋白)、TGF-β1(转化生长因子β1)的蛋白表达水平
TGF-β是肝脏纤维化的重要调节因子，因此也是肝脏纤维化的生物标记物，它定位于细胞质。α-SMA的表达上调是肝脏星形细胞激活的特征性表现，因此是肝脏纤维化的生物标记。α-SMA定位于成纤维细胞、平滑肌细胞。
提取各组小鼠肝脏的蛋白，进行蛋白质印记实验，结果显示，与正常组相比模型组小鼠肝脏α-SMA和TGF-β1蛋白表达水平增高，差异具有显著性；低剂量光皮树油组肝脏α-SMA和TGF-β1蛋白表达水平较模型组稍降低；高剂量光皮树油组肝脏α-SMA和TGF-β1蛋白表达水平较模型组明显降低，差异具有显著性(见图5A、5B)。
说明光皮树油可以剂量依赖性降低小鼠肝纤指标α-SMA，并且可剂量依赖性降低促进肝纤维化形成的因子TGF-β1。
Claims (10)
1.光皮树提取物在制备抗肝脏纤维化制剂中的应用。
2.根据权利要求1所述的应用，其中，所述光皮树提取物是光皮树油；优选地，所述光皮树油是从光皮树的果实和种子中萃取出的脂质物质。
3.根据权利要求1或2所述的应用，其中，所述制剂是食品、药物或保健品。
4.根据权利要求3所述的应用，其中，所述制剂是药物时，所述制剂为口服、注射或灌胃途径给药；优选地，所述注射为静脉注射或腹腔注射。
5.根据权利要求4所述的应用，其中，所述药物的剂型为片剂、胶囊剂、粉针、注射剂或气雾剂；优选地，所述药物还包括一种或多种制药学上可接受的辅料。
6.根据权利要求3所述的应用，其中，当所述制剂是食品或保健品时，还包括一种或多种制剂学上可接受的辅料，如填充剂、口味改善剂、溶剂和/或缓冲剂。
7.根据权利要求1～6任一项所述的应用，其中，所述抗肝脏纤维化指预防、治疗肝脏纤维化或改善肝脏纤维化状态。
8.根据权利要求1～6任一项所述的应用，其中，所述肝脏纤维化是由CCl4诱导的。
9.一种抗肝脏纤维化的制剂，所述制剂包括光皮树提取物。
10.根据权利要求9所述的制剂，其中，所述光皮树提取物是光皮树油；优选地，所述制剂是食品、药物或保健品。
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910378567.5A CN110151815A (zh) | 2019-05-08 | 2019-05-08 | 含光皮树提取物的制剂及其应用 |
| PCT/CN2020/089246 WO2020224649A1 (zh) | 2019-05-08 | 2020-05-08 | 含光皮树提取物的制剂及其应用 |
| US17/595,060 US20220202890A1 (en) | 2019-05-08 | 2020-05-08 | Formulation containing cornus wilsoniana extract and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910378567.5A CN110151815A (zh) | 2019-05-08 | 2019-05-08 | 含光皮树提取物的制剂及其应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110151815A true CN110151815A (zh) | 2019-08-23 |
Family
ID=67633603
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910378567.5A Pending CN110151815A (zh) | 2019-05-08 | 2019-05-08 | 含光皮树提取物的制剂及其应用 |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US20220202890A1 (zh) |
| CN (1) | CN110151815A (zh) |
| WO (1) | WO2020224649A1 (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020224649A1 (zh) * | 2019-05-08 | 2020-11-12 | 中南大学湘雅二医院 | 含光皮树提取物的制剂及其应用 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11990870B2 (en) * | 2022-03-07 | 2024-05-21 | Nuvoton Technology Corporation | Switched resistor for switched driver stage feedback loop |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1284572C (zh) * | 2005-01-25 | 2006-11-15 | 西北师范大学 | 一种天然物质保肝制剂及其制备方法 |
| CN100423768C (zh) * | 2006-04-07 | 2008-10-08 | 成都自豪药业有限公司 | 一种具有预防或治疗急慢性肝病的药物组合物 |
| CN105361146A (zh) * | 2015-11-09 | 2016-03-02 | 劲膳美生物科技股份有限公司 | 一种肝病患者食用的全营养特殊配方食品 |
| CN107912765A (zh) * | 2016-10-07 | 2018-04-17 | 福建奥正投资发展有限公司 | 脂类组件与高粘度含水食品的组合物，其制备方法、组合使用和应用 |
| CN110151815A (zh) * | 2019-05-08 | 2019-08-23 | 中南大学湘雅二医院 | 含光皮树提取物的制剂及其应用 |
-
2019
- 2019-05-08 CN CN201910378567.5A patent/CN110151815A/zh active Pending
-
2020
- 2020-05-08 WO PCT/CN2020/089246 patent/WO2020224649A1/zh active Application Filing
- 2020-05-08 US US17/595,060 patent/US20220202890A1/en active Pending
Non-Patent Citations (2)
| Title |
|---|
| 李旭光等: "食用油与肝纤维化关系的研究进展", 《现代生物医学进展》 * |
| 黄翠莉等: "光皮树籽油功能性作用的研究", 《食品工业科技》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020224649A1 (zh) * | 2019-05-08 | 2020-11-12 | 中南大学湘雅二医院 | 含光皮树提取物的制剂及其应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020224649A1 (zh) | 2020-11-12 |
| US20220202890A1 (en) | 2022-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7700136B2 (en) | Scutellaria barbata extract for the treatment of cancer | |
| WO2013047055A1 (ja) | ヒートショックプロテイン発現誘導剤 | |
| CN110151815A (zh) | 含光皮树提取物的制剂及其应用 | |
| Jeffery et al. | A review of the effectiveness of hibiscus for treatment of metabolic syndrome | |
| CN102133221B (zh) | 一种防治糖代谢紊乱的复方中药提取物及其制备方法 | |
| Ramchoun et al. | Effect of aqueous extract and polyphenol fraction derived from Thymus atlanticus leaves on acute hyperlipidemia in the Syrian Golden Hamsters | |
| US10967027B2 (en) | Extracts of Cyclanthera pedata and formulations and uses thereof | |
| CN107753445A (zh) | 一种银杏内酯k滴丸及其制备方法 | |
| Ghanbari et al. | Effect of microalgae Arthrospira on biomarkers of glycemic control and glucose metabolism: A systematic review and meta-analysis | |
| KR100310979B1 (ko) | 간질환 예방 및 치료용 생약조성물 | |
| CN104523742B (zh) | 一种具有护肝和提高免疫作用的多糖组合物及其应用 | |
| CN109528729A (zh) | 西红花酸在预防非酒精性脂肪肝炎中的应用 | |
| CN109620831A (zh) | 西红花酸在制备治疗非酒精性脂肪肝炎药物中的应用 | |
| CN105025910A (zh) | 用于预防或治疗糖尿病并发症或血管性水肿的含有天然提取物的药物组合物和功能食品 | |
| CN107224443A (zh) | 保护肝脏免于损伤及纤维化的虾红素蚬精护肝配方 | |
| CN105853402B (zh) | 一种萜类复合酯的用途 | |
| Gayoor et al. | Ethnopharmacological Studies of Argemone Mexicana for the Management of Psoriasis Followed by Molecular Techniques Through Metabolomics | |
| TWI607755B (zh) | 麥角固醇之應用 | |
| CN104491496B (zh) | 天麻素/天麻粉在制备抗肝纤维化药物中的应用 | |
| CN102641312A (zh) | 石榴花多酚在制备治疗非酒精性脂肪肝的药物中的用途 | |
| Safithri et al. | Blood Glucose Level, Langerhans Pancreas and Lipid Profile of Diabetic Rats After Administration of Red Betel, Ginger and Cinnamon Combination Extract | |
| CN1887302A (zh) | 鬼针草总黄酮在制备防治肝纤维化药物中的应用 | |
| CN101596202A (zh) | 丹参酮iia乳剂在治疗肝病中的应用 | |
| KR102676056B1 (ko) | 비알코올성 지방간 질환의 치료 또는 예방용 의약의 제조에서의 트리아세틸-3-하이드록시페닐아데노신의 용도 | |
| Gabi et al. | SYNERGISTIC EFFECT OF FRUITS EXTRACTS OF Balanites aeqyptiaca AND Adansonia digitata ON LIPIDERMIC PARAMETERS OF DIABETICS ALBINO RAT |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190823 |